Which company produces tepotinib?

Tepotinib is a methionine tyrosine kinase inhibitor used to treat various methionine-overexpressing solid tumors. It was originally developed in 2009 by a collaboration between EMD Serono Corporation and the University of Texas M.D. Anderson Cancer Center and has since been studied in the treatment of neuroblastoma, gastric cancer, non-small cell lung cancer and hepatocellular carcinoma.

Methionine is an ideal target in the treatment of certain solid tumors because it appears to play a critical role, directly or indirectly, in the growth and proliferation of tumors in which it is overexpressed and/or mutated. Includes exon 14 skipped variants - which inhibit methionine phosphorylation and subsequent downstream signaling pathways to inhibit tumor cell proliferation, anchorage-independent growth and methionine-dependent tumor cell migration. Tepotinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients exhibiting MET exon 14 skipping mutations.

The original drug of Tepotinib is a new type of drug that is not yet on the market in China and therefore has not been included in the medical insurance. The price of Tepotinib original drug specifications225mg*30 tablets per box listed overseas is around RMB 80,000 (the price may fluctuate due to the exchange rate). It has been on the market for a short time and is expensive. There are also Tepotinib generic drugs produced in other countries. The price of 225mg*60 tablets produced by a Lao pharmaceutical factory is around RMB 8,600 per box (the price may fluctuate due to the exchange rate). The ingredients of generic drugs produced abroad are basically the same as those of the original drug. For specific prices and drug details, please consult Yaode Medical Consultant.